YO10 5NY Heslington
+1 (240) 306-2050
Xceleron Announces New Investment and Move to Purpose-Built Laboratories in U.S.
Demand in translational science drives need for additional equipment
Xceleron is relocating senior analytical staff to Germantown from York, hiring new staff in Maryland and retaining a strong study design and project management presence in the UK. The Germantown facility was opened for business in 2008 and has conducted a range of customer studies including absolute bioavailability, metabolism and general pharmacokinetic investigations. 12,000 samples have been analyzed on site for a growing client base of pharmaceutical and biotech companies.
Xceleron intends to augment its analytical capability in Germantown with the latest in highly sensitive LC-MS/MS technology. This addition will create the first laboratory of its kind in which all forms of microtracer and microdose investigations can be conducted in one custom-built facility.
Stuart Best, Vice President Analytical Operations added: "The combined ruggedness of AMS and the specificity of the most sensitive LC-MS/MS will enable a highly cost-effective and safe bridge from discovery to the clinic."
Xceleron CEO Michael Butler commented: "Our customers told us that they want access to the best analytical platforms in translational science. We are providing that access with the most experienced team in the business and in one highly efficient and purpose built location. This is a first-of-a-kind combination from Xceleron that we believe will add to our customers' drive for Phase 2-readiness"
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.